View Financial HealthZenith Capital 配当と自社株買い配当金 基準チェック /06Zenith Capital配当金を支払った記録がありません。主要情報n/a配当利回り-22.1%バイバック利回り総株主利回り-22.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.お知らせ • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canadaお知らせ • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.お知らせ • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.お知らせ • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.お知らせ • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.お知らせ • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020お知らせ • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.決済の安定と成長配当データの取得安定した配当: ZHCL.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ZHCL.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Zenith Capital 配当利回り対市場ZHCL.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ZHCL.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (ZHCL.F) (最長3年)n/a注目すべき配当: ZHCL.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ZHCL.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ZHCL.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ZHCL.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:26終値2026/05/22 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zenith Capital Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.
お知らせ • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canada
お知らせ • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.
お知らせ • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.
お知らせ • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.
お知らせ • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
お知らせ • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.
お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020
お知らせ • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.